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Abstract. 
 
FGF-2 and VEGF are potent angiogenesis 
inducers in vivo and in vitro. Here we show that FGF-2 
induces VEGF expression in vascular endothelial cells 
through autocrine and paracrine mechanisms. Addition 
of recombinant FGF-2 to cultured endothelial cells or 
upregulation of endogenous FGF-2 results in increased 
VEGF expression. Neutralizing monoclonal antibody 
to VEGF inhibits FGF-2–induced endothelial cell pro-
liferation. Endogenous 18-kD FGF-2 production up-
regulates VEGF expression through extracellular inter-
action with cell membrane receptors; high-
 
M
 
r
 
 FGF-2 
(22–24-kD) acts via intracellular mechanism(s). During 
angiogenesis induced by FGF-2 in the mouse cornea, 
the endothelial cells of forming capillaries express 
VEGF mRNA and protein. Systemic administration of 
neutralizing VEGF antibody dramatically reduces 
FGF-2-induced angiogenesis. Because occasional fibro-
blasts or other cell types present in the corneal stroma 
show no significant expression of VEGF mRNA, these 
findings demonstrate that endothelial cell-derived 
VEGF is an important autocrine mediator of FGF-
2-induced angiogenesis. Thus, angiogenesis in vivo can 
be modulated by a novel mechanism that involves the 
autocrine action of vascular endothelial cell-derived 
FGF-2 and VEGF.
 
A
 
ngiogenesis
 
, the formation of capillaries from pre-
existing blood vessels, occurs in a variety of physi-
ological and pathological settings, including em-
bryonic development, wound healing, and tumor growth
(Folkman and Klagsbrun, 1987; Folkman, 1991, 1992;
Breier et al., 1997; Risau, 1997). Numerous studies have
shown that angiogenesis is required for the growth and me-
tastasis of solid tumors (Weidner et al., 1991; Horak et al.,
1992; Macchiarini et al., 1992; Wakui et al., 1992; Vartanian
et al., 1994). A number of cytokines and growth factors
modulate angiogenesis in vitro and in vivo with a paracrine
mode of action. Among these factors, basic fibroblast
growth factor (FGF-2)
 
1
 
 and vascular endothelial growth
factor
 
 
 
(VEGF) are the most potent angiogenesis inducers
(for reviews see Basilico and Moscatelli, 1992; Ferrara et al.,
1992; Bikfalvi et al., 1997; Ferrara and Davis-Smyth, 1997).
FGF-2 is the prototype member of a family of 13 struc-
turally related, heparin-binding growth factors (for recent
review see Bikfalvi et al., 1997). It is expressed ubiqui-
tously in cells of mesodermal and neuroectodermal origin,
and in a variety of tumor cells. In vitro, FGF-2 is a potent
mitogen for different cell types, including vascular endo-
thelial cells and fibroblasts. With cultured endothelial
cells, FGF-2 induces an angiogenic phenotype consisting
of increased proliferation, migration, proteinase produc-
tion, and expression of specific integrins (Moscatelli et al.,
1986
 
a
 
; Klein et al., 1993, 1996). In vivo FGF-2 is a potent
inducer of angiogenesis and has pleiotropic effects on de-
velopment and differentiation in various organs (Basilico
and Moscatelli, 1992; Bikfalvi et al., 1997). However, mice
genetically deficient in FGF-2 (FGF-2 knockout) have no
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: BAE, bovine aortic endothelial cells;
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blast growth factor-2; HAE, human aortic endothelial cells; HMW FGF-2,
 
high molecular weight fibroblast growth factor-2; HUVE, human umbili-
cal vein endothelial cells; LMW FGF-2, low molecular weight fibroblast
growth factor-2; rFGF-2, recombinant fibroblast growth factor-2; VEGF,
vascular endothelial growth factor; vWF, von Willebrand factor.
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apparent defects related to impaired angiogenesis (Ortega
et al., 1998; Zhou et al., 1998).
FGF-2 exists in four different molecular weight iso-
forms: 18-kD or low molecular weight (LMW) FGF-2, and
22-, 22.5-, and 24-kD or high molecular weight (HMW)
FGF-2. The HMW forms derive from alternative transla-
tion initiation (CUG) codons and contain the complete
LMW sequence in addition to an NH
 
2
 
-terminal extension
of varying length (Moscatelli et al., 1987; Sommer et al.,
1987; Florkiewicz and Sommer, 1989; Prats et al., 1989).
The different forms of FGF-2 have been associated with
different cell functions and cellular compartmentalization.
LMW FGF-2 is released by the cells and stimulates cell
migration, proliferation, and FGF receptor downregula-
tion through binding to surface receptors; HMW FGF-2
forms primarily localize to the nucleus and modulate cell
proliferation (Bugler et al., 1991; Mignatti et al., 1991; Flor-
kiewicz et al., 1991; Quarto et al., 1991
 
a
 
,
 
b
 
; Renko et al.,
1991; Bikfalvi et al., 1995).
The biological activity of FGF-2 is mediated through a
dual receptor system consisting of four high-affinity, ty-
rosine kinase receptors and low-affinity, heparan sulfate
proteoglycans located at the cell surface (Moscatelli, 1987;
Flaumenhaft et al., 1989; Lee et al., 1989; Dionne et al.,
1990; Keegan et al., 1991; Partanen et al., 1991). However,
FGF-2 lacks a signal peptide that directs secretion through
the classical secretory pathway (Abraham et al., 1986). Al-
though the mechanism(s) by which FGF-2 is released from
cells is/are still unknown (Mignatti and Rifkin, 1991; Mig-
natti et al. 1991, 1992), FGF-2 is found extracellularly and
modulates several cell functions in an autocrine manner
(Sato and Rifkin, 1988; Mignatti et al., 1991; Sato et al.,
1991; Peverali et al., 1994; Bikfalvi et al., 1995; Klein et al.,
1996). Because of its high affinity for heparin and heparan
sulfate glycosaminoglycans, significant amounts of FGF-2
are associated with the extracellular matrix of in vitro cell
cultures (Vlodavski et al., 1987; Bashkin et al., 1989; Flau-
menhaft et al., 1989; Rojeli et al., 1989). In vivo, FGF-2 has
been detected in the basal lamina of blood capillaries, pri-
marily at sites of vessel branching, and in the endothelium
of the capillaries of some tumors (Folkman et al., 1988; Di-
Mario et al., 1989; Cordon et al. 1990; Schulze-Osthoff
et al., 1990), suggesting that endothelial cell-derived FGF-2
may mediate angiogenesis with an autocrine mode of ac-
tion. This hypothesis is supported by the observation that
FGF-2 has an autocrine effect on several cell functions re-
quired for angiogenesis, including proliferation, migration,
proteinase production, and integrin expression (Sato and
Rifkin, 1988; Mignatti et al., 1991; Sato et al., 1991; Pever-
ali et al., 1994; Bikfalvi et al., 1995; Klein et al., 1996).
VEGF, the prototype member of a family of four struc-
turally related growth factors, is a potent mitogen for mi-
cro- and macrovascular endothelial cells but lacks appre-
ciable mitogenic activity for other cell types (Ferrara and
Davis-Smyth, 1997; Senger et al., 1993). VEGF exists in
five molecular species of 121, 145, 165, 189, and 206 amino
acids (VEGF
 
121
 
, VEGF
 
145
 
, VEGF
 
165
 
, VEGF
 
189
 
, VEGF
 
206
 
)
that derive from exon splicing of a single gene (Houck
et al., 1991; Keck et al., 1989; Leung et al., 1991; Tisher et
al., 1991; Poltorak et al., 1997). VEGF
 
165
 
, a 46-kD ho-
modimeric glycoprotein, is the predominant isoform pro-
duced by a variety of normal and transformed cells.
VEGF
 
121
 
 is a freely soluble protein. The other VEGF iso-
forms show increased affinity for heparan sulfate pro-
teoglycans: VEGF
 
165
 
 is soluble although a fraction can re-
main bound to the extracellular matrix; VEGF
 
189
 
 and
VEGF
 
206
 
 are almost exclusively sequestered in the extra-
cellular matrix (Ferrara et al., 1992; Houck et al., 1992;
Park et al., 1993).
The promoter region of VEGF contains hypoxia-respon-
sive elements in addition to several potential Ap-1, Ap-2
and Sp-1 binding sites, indicating that VEGF transcription
can be enhanced in response to multiple stimuli (Tisher et
al., 1991; Levy et al., 1995; Liu et al., 1995). Oxygen tension
plays a major role in the regulation of VEGF expression in
a variety of cell types, including endothelial cells. Several
findings have implicated VEGF as the major mediator of
the angiogenic effect of hypoxia (Shweiki et al., 1992;
Goldberg and Schneider, 1994; Minchencko et al., 1994;
Liu et al., 1995; Shima et al., 1995; Forsythe et al., 1996). In
addition, several cytokines and growth factors, as well as
tumor promoters upregulate VEGF expression in many
cell types (Garrido et al., 1993; Goldman et al., 1993;
Pertovaara et al., 1994; Li et al., 1995; Tsai et al., 1995;
Ryuto et al., 1996). It has been proposed that VEGF may
act as a paracrine mediator for indirect-acting angiogenic
factors, such as transforming growth factor beta (Brogi et
al., 1994). However, the effect of cytokines and growth fac-
tors on VEGF expression in vascular endothelial cells has
not been investigated.
Numerous lines of evidence implicate VEGF as a piv-
otal factor in the regulation of normal and pathological
vasculogenesis and angiogenesis. VEGF promotes angio-
genesis in different experimental models in vitro and in
vivo (Leung et al., 1989; Plouet et al., 1989; Pepper et al.,
1992; Nicosia et al., 1994; Phillips et al., 1995). The loss of
even a single VEGF allele results in embryonic lethality,
showing the irreplaceable role of this factor in the devel-
opment of the vascular system (Carmeliet et al., 1996; Fer-
rara et al., 1996). In addition, VEGF has been shown to
have therapeutic effects on coronary and limb ischemia
(Takeshita et al., 1994; Pearlman et al., 1995; Harada et al.,
1996; Isner et al., 1996). VEGF mRNA is markedly upreg-
ulated in the majority of human tumors so far examined
(for review see Ferrara and Davis-Smyth, 1997). Its ex-
pression in several tumors has been correlated with high
vascularity, lymph node metastasis, and liver metastasis,
and a poorer prognosis than VEGF-negative tumors (Toi
et al., 1994; Maeda et al., 1996). Antibodies to VEGF or
expression of a dominant-negative VEGF receptor inhibit
tumor growth in vivo without affecting tumor cell prolifer-
ation in vitro. In animals treated with anti-VEGF antibod-
ies the density of blood vessels in tumor sections is lower
than in the tumors of control animals, showing that the in-
hibitory effect of the antibody on tumor growth is medi-
ated by a blockage of the angiogenic activity of VEGF
(Kim et al., 1993; Millauer et al., 1994; Warren et al., 1995;
Borgstrom et al., 1996). These findings implicate VEGF as
the major tumor angiogenesis factor so far identified.
In addition to promoting vasculogenesis and angiogene-
sis, VEGF enhances vascular permeability and induces
fenestrations in the endothelium of small capillaries and
venules (Senger et al., 1983; Roberts and Palade, 1995).
An increase in vascular permeability may be required for 
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angiogenesis during tumor growth and wound healing
(Dvorak, 1986). The observation of VEGF expression
around microvessels whose endothelium is normally qui-
escent has generated the hypothesis that VEGF is also re-
quired for the maintenance of the differentiated state of
blood vessels (Ferrara et al., 1992; Alon et al., 1995).
The findings that FGF-2 can modulate angiogenesis
with an autocrine mechanism (Sato and Rifkin, 1988; Mig-
natti et al., 1991; Sato et al., 1991; Peverali et al., 1994; Bik-
falvi et al., 1995; Klein et al., 1996) and that FGF-2 and
VEGF have synergistic effects on angiogenesis (Pepper et al.,
1992) prompted us to investigate potential interactions be-
tween these two potent angiogenic factors in vascular en-
dothelial cells. Here we report that FGF-2 modulates en-
dothelial cell expression of VEGF through both autocrine
and paracrine mechanisms of action. In vivo the endothe-
lial cells of quiescent vessels do not express VEGF; upon
stimulation with FGF-2 the endothelium of newly forming
capillaries produces VEGF. The systemic administration
of VEGF antibody to mice that received corneal implants
of FGF-2 pellets results in a dramatic decrease in angio-
genesis, implicating endothelial cell VEGF as a major me-
diator of the angiogenic activity of FGF-2.
 
Materials and Methods
 
Materials
 
Human recombinant VEGF
 
165
 
 and mouse recombinant VEGF
 
165
 
 were
purchased from R & D Systems, Inc. (Minneapolis, MN); anti-human
VEGF antibody (
 
a
 
VEGF sc507) was purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA); the neutralizing monoclonal antibody to
human VEGF, mAb #577B11, was a gift of Texas Biotechnology, Inc.
(Houston, TX); mouse and rabbit nonimmune (n.i.) IgG were purchased
from Sigma Chemical Co. (St. Louis, MO); human recombinant FGF-2
was obtained from Scios Nova and Synergen, Inc. (Boulder, CO); anti–
rFGF-2 antibody has been described (R58; Pintucci et al., 1996); anti-von
Willebrand factor antibody (vWF A0082) was purchased from Dako
Corp. (Carpinteria, CA), and doxycycline from Sigma Chemical Co. pro-
tein concentrations were measured by the Bio-Rad DC protein assay re-
agent (Bio-Rad Laboratories, Hercules, CA) using BSA as a standard.
 
Cells and Media 
 
Bovine aortic endothelial cells (BAE) and bovine capillary endothelial
cells (BCE) were isolated as described (Folkman et al., 1979) and grown
in alpha modified minimum essential medium (
 
a
 
MEM; Fisher Scientific
Co., Pittsburgh, PA) supplemented with 5% calf serum and 2mM 
 
l
 
-glu-
tamine (GIBCO BRL, Gaithersburg, MD). These cells were used be-
tween passages 6 and 15 in culture. Human umbilical vein endothelial
(HUVE) cells and human aortic endothelial (HAE) cells were purchased
from Clonetics (San Diego, CA). These cells were grown in endothelial
cell basal medium-2 (Clonetics) containing 2% FCS and the endothelial
cell growth supplements provided by the company. Both HUVE and
HAE cells were used between passages 3 and 5 in culture. NIH 3T3 fibro-
blasts transfected with the cDNAs for human low 
 
M
 
r
 
 FGF-2 (LMW FGF-2),
high 
 
M
 
r
 
 FGF-2 (HMW FGF-2), or all FGF-2 isoforms (wt FGF-2), and
NIH 3T3 cells transfected with the vector alone (ZipNeo) have been de-
scribed (Quarto et al., 1991
 
a
 
,
 
b
 
; Bikfalvi at al., 1995). These cells were
grown in DME supplemented with 10% FBS, 2 mM 
 
l
 
-glutamine, and 500
 
m
 
g/ml geneticin (G418; Sigma Chemical Co.).
 
Cell Proliferation Assay
 
HUVE or HAE cells were seeded into 96-well plates (2.5 
 
3 
 
10
 
3
 
 cells/well)
in 50 
 
m
 
l of endothelial cell basal medium-2 supplemented with heparin
and 1% FCS. After overnight incubation, FGF-2 or VEGF were added to
a final concentration of 10 or 30 ng/ml, respectively, in the presence or ab-
sence of 10 
 
m
 
g/ml of either anti-human VEGF monoclonal antibody or
anti–FGF-2 antibody or mouse n.i. IgG. Control cultures received equiva-
lent volumes of medium with no addition. The medium was replaced ev-
ery third day with fresh medium with or without addition of FGF-2,
VEGF, and the IgGs. Triplicate samples were trypsinized every 24 h and
counted with a hemocytometer.
 
Transfection of NIH 3T3
Cells with FGF-2 cDNA under Control by the 
Tetracycline-dependent Transactivator
 
EcoRI–EcoRI cDNAs for LMW and HMW FGF-2 were cloned into the
EcoRI site of the plasmid pUHD10-3 (provided by H. Bujard, Zentrum
für Molekulare Biologie der Universität, Heidelberg, Germany), which
contains the binding sequence for the tetracycline-controlled transactiva-
tor (rtTA) in front of a multiple cloning site (Gossen et al., 1995). NIH
3T3 cells were transfected with the plasmid pUHD172-1Neo (also pro-
vided by H. Bujard), which contains a mutagenized form of rtTA spliced
to a nuclear translocation sequence and the neomycin resistance gene
(Gossen et al., 1995). Transfected cells were selected in medium contain-
ing 500 
 
m
 
g/ml of G418. One clone of G418-resistant cells that constitu-
tively expressed rtTA was cotransfected with the plasmids pUHD–LMW
FGF-2 or pUHD–HMW FGF-2 and the plasmid pCEP4 containing the
hygromycin resistance gene (Invitrogen, Carlsbad, CA). Stable cotrans-
fectants were selected in medium containing 500 
 
m
 
g/ml of both G418 and
hygromycin (Calbiochem-Novabiochem, San Diego, CA). Hygromycin/
G418-resistant cells were characterized for FGF-2 expression by Western
blotting of extracts of cells grown in serum-free medium with or without 1
 
m
 
g/ml of doxycycline for 24 h.
 
Preparation of SK-Hep1 Cell-conditioned Medium 
 
Confluent cultures of SK-Hep1 cells in 150 cm
 
2
 
 culture flasks were washed
twice with PBS and incubated for 17 h in the presence of 15 ml of serum-
free DME. The culture supernatant was centrifuged at 1,000 
 
g
 
 for 15 min
and either used immediately or stored at 
 
2
 
20
 
8
 
C.
 
Northern Blotting
 
Total RNA was extracted from cells with the Trizol reagent (GIBCO
BRL) according to the manufacturer’s instructions. The RNA (20 
 
m
 
g) was
run in a 1% formaldehyde–agarose gel and transferred to a positively
charged nylon membrane (Boehringer Mannheim Biochemicals, India-
napolis, IN). The blot was prehybridized in digoxygenin (DIG) Easy Hyb
(Boehringer Mannheim Biochemicals) for 2 h at 42
 
8
 
C and then hybridized
overnight at 42
 
8
 
C with a 403-bp DIG-labeled cDNA probe to human
VEGF
 
121
 
 obtained by reverse transcriptase–PCR using the primers de-
scribed in Houk et al. (1991). The cDNA was labeled by running the PCR
reaction in the presence of DIG-labeled nucleotides (Boehringer Mann-
heim Biochemicals). After hybridization, the membrane was washed twice
in 2
 
3
 
 SSC, 0.1% SDS at room temperature for 15 min and twice in 1
 
3
 
SSC, 0.1% SDS at 50
 
8
 
C for 15 min. The detection of the probe was per-
formed using the Genius 7 kit (Boehringer Mannheim Biochemicals) ac-
cording to the manufacturer’s instructions. The membranes were exposed
to autoradiographic films (Hyperfilm MP; Amersham Life Technologies,
Arlington Heights, IL) for 1 min.
 
Western Blotting
 
Confluent endothelial cells or NIH 3T3 cells in 100-mm dishes were
washed with PBS and incubated overnight in serum-free medium. The
conditioned medium was concentrated 80-fold by ultrafiltration in Centri-
con tubes (Amicon, Inc., Beverly, MA). The cells were lysed in 100 mM
Tris-HCl, pH 8.1, containing 0.5% Triton X-100, 10 
 
m
 
g/ml leupeptin
(Sigma Chemical Co.), and 400 
 
m
 
M Pefablock (Boehringer Mannheim
Biochemicals). Cell extract protein (200 
 
m
 
g from endothelial cells, 50 
 
m
 
g
from NIH 3T3 cells) or concentrated conditioned medium was electro-
phoresed in SDS–12% polyacrylamide gel under reducing conditions and
then blotted to a polyvinylidene difluoride membrane (Immobilon P; Mil-
lipore Corp., Waters Chromatography, Bedford, MA) for 4 h at 45 V. The
membrane was incubated with 5% skim milk (Carnation; Nestlé Food
Co., Glendale, CA) in 20 mM Tris buffer, pH 7.4, overnight at 4
 
8
 
C to
block nonspecific binding. VEGF or FGF-2 were detected by incubating
the membrane with 0.2 
 
m
 
g/ml of antibody to human VEGF (
 
a
 
VEGF
sc507; Santa Cruz Biotechnology, Inc.) or to human rFGF-2 (R58; Pin-
tucci et al., 1996) for 1 h at room temperature. After incubation with 
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horseradish peroxidase-conjugated donkey anti–rabbit IgG (1:5,000) for 1
h (Amersham Life Technologies), immune complexes were detected with
the enhanced chemiluminescence ECL™ detection system (Amersham
Life Technologies). The membranes were exposed to autoradiographic
films (Hyperfilm MP; Amersham Life Technologies) for 10 s–1 min.
 
Metabolic Labeling and Immunoprecipitation
 
Confluent endothelial cells were incubated for 2 h with SK-Hep1 cell-con-
ditioned medium or with control medium. After incubation with methionine/
cysteine-free DME for 1 h, the medium was replaced with methionine/cys-
teine-free DME containing 150 
 
m
 
Ci/ml of 
 
35
 
S-methionine/cysteine (ICN
Biomedicals, Inc., Costa Mesa, CA) and the incubation was continued for
4 h. The medium was collected and centrifuged at 1,000 
 
g 
 
for 5 min, di-
luted 1:1 with RIPA buffer (PBS, 1% Tergitol, 0.5% deoxycholic acid,
0.1% SDS) and incubated with 1 
 
m
 
g/ml of anti-human VEGF IgG
(
 
a
 
VEGF sc507; Santa Cruz Biotechnology, Inc.) for 1 h followed by 1 h of
incubation with protein A–Agarose (Boehringer Mannheim Biochemi-
cals). After washing three times with RIPA buffer, the resin was loaded
onto a SDS–12% polyacrylamide gel and run under reducing conditions.
The gel was fixed in 30% methanol and 10% acetic acid for 30 min and
then incubated for 30 min in Amplify (Amersham Life Technologies).
Dried gels were exposed to autoradiographic films (Hyperfilm 
 
b
 
max; Am-
ersham Life Technologies) for 7 d at 
 
2
 
80
 
8
 
C.
 
Densitometry
 
Northern blot and Western blot bands were analyzed with a Shimadzu
scanning densitometer (model C6-93-01PC; Shimadzu Scientific Instru-
ments, Inc., Columbia, MD) using dedicated software.
 
In Vivo Angiogenesis Assay 
 
Angiogenesis assays in the mouse cornea were performed as described
(Chen et al., 1995). Briefly, a corneal pocket was created with a modified
von Graefe cataract knife in both eyes of 4–6-wk-old C57B mice (The
Jackson Laboratory, Bar Harbor, ME). One 0.34 
 
3 
 
0.34-mm sucrose alu-
minum sulfate (Bukh Meditec, Copenhagen, Denmark) pellet coated with
hydron polymer type NCC (IFN Sciences, New Brunswick, NJ), contain-
ing 50 ng of rFGF-2 was implanted into each pocket. Pellets without
rFGF-2 were used as negative controls. The corneas were routinely exam-
ined by slit-lamp biomicroscopy on postoperative days 5–7. After exami-
nation, the mice were killed and the eyes excised, embedded in tissue-
freezing medium (Triangle Biomedical Sciences, Durham, NC), and then
frozen in a mixture of dry ice and 2-methylbutane (Fisher Scientific Co.).
Frozen eyes were stored at 
 
2
 
80
 
8
 
C.
 
Immunohistochemistry
 
30-
 
m
 
m frozen sagittal sections of mouse eyes were fixed in 4% parafor-
maldehyde in PBS for 15 min and then incubated with 1 
 
m
 
g/ml goat n.i. IgG
for 1 h to block nonspecific binding. To detect VEGF or von Willebrand
factor (vWF), the specimens were incubated overnight at 4
 
8
 
C with 2 
 
m
 
g/ml
of rabbit antibody to murine VEGF (
 
a
 
VEGF sc507) or with 2 
 
m
 
g/ml of
rabbit antibody to human vWF that cross-reacts with mouse vWF. Rabbit
n.i. IgG was used as a negative control. The sections were washed in 20
mM Tris buffer, pH 7.4, incubated with biotinylated goat anti–rabbit anti-
serum (Vectastain ABC Kit; Burlingame, CA) for 45 min and subsequently
in 1% Triton X-100 (Sigma Chemical Co.) for 30 min. After washing in 20
mM Tris buffer, pH 7.4, avidin–biotin amplification was performed ac-
cording to the manufacturer’s instructions (Vectastain ABC Kit). Anti-
gen–antibody complexes were detected by incubation with 3,3 diami-
nobenzamine (Sigma Chemical Co.) at room temperature for 10 min. The
slides were counterstained with Gil’s hematoxylin 1 (Sigma Chemical Co.).
 
In Situ Hybridization
 
Single-stranded, sense (S) and antisense (AS) RNA probes were gener-
ated by run-off in vitro transcription in the presence of DIG-labeled nu-
cleotides (Transcription kit; Boehringer Mannheim Biochemicals) of a lin-
earized pCR™II plasmid (TA cloning kit; Invitrogen) containing the 403-bp
VEGF cDNA insert used for Northern blotting. 30-
 
m
 
m frozen sections of
mouse eyes were fixed in 4% paraformaldehyde in PBS for 15 min, digested
with proteinase K (1 
 
m
 
g/ml; Boehringer Mannheim Biochemicals) at room
temperature for 10 min and then acetylated with 0.25% acetic anhydride
in 100 mM triethanolamine. Hybridization with 0.2 
 
m
 
g/ml of the DIG-labeled
S or AS VEGF riboprobe was performed in deionized 40% formamide,
10% dextran sulphate, 1
 
3
 
 Denhardt’s solution, 4
 
3
 
 SSC, 10 mM DTT, and 1
mg/ml sheared salmon sperm DNA overnight at 42
 
8
 
C in a moist chamber.
The slides were washed three times in 0.1
 
3 
 
SSC for 20 min at 55
 
8
 
C and di-
gested with RNase A (20 
 
m
 
g/ml; Boehringer Mannheim Biochemicals).
The immunological detection was performed using sheep anti-DIG IgG
conjugated with alkaline phosphatase 0.5 U/ml (anti–DIG-AP Fab fragment;
Boehringer Mannheim Biochemicals) according to the manufacturer’s in-
structions. The chromogenic reaction with NBT/BCIP (Boehringer Mann-
heim Biochemicals) was developed in 100 mM Tris buffer, 50 Mm NaCl,
50 mM MgCl
 
2, 
 
and 1 mM levamisole, pH 9.5, for 4 h at room temperature.
 
Results
 
FGF-2 Stimulates Endothelial Cell Expression of VEGF 
through Both Autocrine and Paracrine Mechanisms
 
To test the effect of FGF-2 on VEGF expression by endo-
thelial cells, confluent BCE or BAE cells were incubated
for 4 h with serum-free medium or with medium contain-
ing 10 ng/ml of human recombinant FGF-2 (rFGF-2).
Northern blotting with a cDNA probe to human VEGF
showed a band of 3.9 kb, consistent with the expected size
of VEGF mRNA (Tischer et al., 1991; Shima et al., 1995)
(Fig. 1 
 
A
 
). The intensity of this band was ten- and fivefold
higher in rFGF-2–treated BCE and BAE cells, respec-
tively, than in control cells. Western blotting under nonre-
ducing conditions with antibody to human VEGF showed
a band of 46 kD that comigrated with human recombinant
VEGF
 
165
 
 (R & D Systems) in medium conditioned by
FGF-2–treated endothelial cells. This band was very faint
or absent in the conditioned medium or extracts of control
BCE or BAE cells (Fig. 1 
 
B
 
). Reverse transcriptase–PCR
with primers for VEGF (Houk et al., 1991) showed two
transcripts whose sequences corresponded to VEGF
 
165
 
and VEGF
 
121
 
 and a minor transcript corresponding to
VEGF
 
189 
 
(data not shown). However, Western blotting of
cell-conditioned medium or extract showed no immunore-
active proteins other than VEGF
 
165
 
. These data showed
that exogenous FGF-2 upregulates the expression of
VEGF
 
165
 
 in cultured endothelial cells.
The endothelial cells we used had been selected in our
laboratory for low expression of endogenous FGF-2, rela-
tive to other strains of BCE or BAE cells. The cells ex-
pressed 18, 22, and 24 kD FGF-2, as assessed by Western
blotting with antibody to human rFGF-2 (Fig. 2 
 
A
 
). Be-
cause in the absence of exogenous rFGF-2 BCE or BAE
cells did not express VEGF (Fig. 1), this finding indicated
that either VEGF expression is regulated only by exoge-
nous FGF-2 or that the levels of endogenous FGF-2 in our
endothelial cells were too low to induce VEGF expression.
To test these hypotheses, BCE cells were incubated with
SK-Hep1 hepatoma cell-conditioned medium, which up-
regulates endothelial cell expression of FGF-2 mRNA
(Peverali et al., 1994). Consistent with previous findings
(Moscatelli et al., 1986
 
b
 
; Peverali et al., 1994), Western
blotting of concentrated SK-Hep1 cell-conditioned me-
dium showed no detectable FGF-2 (
 
,
 
0.25 ng/ml) (Fig. 2
 
A
 
). Incubation with SK-Hep1 cell-conditioned medium re-
sulted in a five- and twofold increase in LMW FGF-2 and
HMW FGF-2, respectively (Fig. 2 
 
A
 
), and in a fourfold in-
crease in VEGF mRNA (Fig. 2 
 
B
 
). Addition of neutraliz-
ing rFGF-2 IgG (10 
 
m
 
g/ml) decreased VEGF mRNA ex-
pression to control levels. In contrast, n.i. IgG was ineffective 
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(Fig 2 B). Similarly, immunoprecipitation experiments
showed that 2.5-fold higher levels of VEGF165 were pro-
duced by endothelial cells exposed to the conditioned me-
dium relative to cells incubated with control medium. Ad-
dition of anti–rFGF-2 antibody abolished this effect, whereas
n.i. serum was ineffective (data not shown). Because SK-
Hep1 cell-conditioned medium contains no FGF-2, these
results showed that upregulation of endogenous FGF-2 re-
sults in increased expression of endothelial cell VEGF165.
VEGF Mediates FGF-2–induced Proliferation of 
Endothelial Cells
To test the functional significance of VEGF produced by
endothelial cells stimulated with FGF-2, we characterized
the effect of neutralizing monoclonal antibody to VEGF
on the proliferation of endothelial cells treated with FGF-2.
Because the monoclonal antibody we used was raised
against human VEGF, HUVE or HAE cells were used for
these experiments. As shown in Fig. 3 (A and C), addition
of VEGF antibody to FGF-2–treated HUVE or HAE cells
inhibited cell proliferation by 100 and 50%, respectively.
In control cultures, the VEGF antibody completely neu-
tralized the activity of recombinant VEGF on HUVE or
HAE cell proliferation (Fig. 3, B and D). Thus, endothe-
lial cell-derived VEGF is an important downstream medi-
ator of the mitogenic activity of FGF-2.
Endogenous LMW FGF-2 and HMW
FGF-2 Modulate VEGF Expression through Different 
Mechanisms of Action
Our endothelial cells expressed both LMW FGF-2 and
HMW FGF-2 (Fig. 2 A). To characterize possible differen-
tial roles of the FGF-2 isoforms in VEGF upregulation we
used a panel of NIH 3T3 cell clones transfected with the
cDNAs for either LMW FGF-2 (LMW FGF-2), HMW
FGF-2 (HMW FGF-2), or all FGF-2 isoforms (wt FGF-2).
NIH 3T3 cells transfected with the vector alone (ZipNeo)
were used as control. By Western blotting, all the clones of
FGF-2 transfectants used in our experiments expressed
comparable levels of FGF-2 (Fig 4 A). Control cells trans-
fected with the vector alone produced no FGF-2.
Western blotting of conditioned medium under reduc-
ing conditions showed two bands of 23 and 21 kD, respec-
tively, consistent with two glycosylation variants of VEGF165
(Houck et al., 1991) in medium conditioned by the FGF-2
transfectants (Fig. 4 B). Medium conditioned by LMW
FGF-2 or HMW FGF-2 transfectants contained comparable
levels of VEGF165; wt FGF-2 cell clones expressed higher
levels of VEGF165. In contrast, control cells transfected
with the vector alone produced no VEGF. No other iso-
forms of VEGF were detected in the conditioned medium
or cell extracts (data not shown) of any of the transfected
cells (Fig. 4 B). Northern blotting of RNA from the FGF-2
transfectants with a cDNA probe to human VEGF showed a
band of 3.9 kb, consistent with the expected size of murine
VEGF mRNA (Shima et al., 1995). This band was absent
in control, vector-transfected cells (Fig. 4 C).
To rule out the possibility that the differences in VEGF ex-
pression between the FGF-2 transfectants and the control
cells reflected clonal variability, we used clones of NIH 3T3
cells transfected with the cDNAs for either LMW FGF-2
or HMW FGF-2 whose expression was controlled by the tet-
racycline-dependent transactivator (Gossen et al., 1995).
These transfectants had comparable growth rates in the
Figure 1. FGF-2 induces
VEGF expression in endo-
thelial cells. (A) Northern
blotting analysis of total
RNA (20 mg) from BAE or
BCE cells treated with
rFGF-2 (10 ng/ml) or with
control medium (C) for 4 h.
The RNA blot was hybrid-
ized with a DIG-labeled
cDNA probe for human
VEGF as described in Mate-
rials and Methods. GAPDH
mRNA is shown as a control.
The position of 28 S and 18 S
ribosomal RNA is shown on
the left. This experiment was
repeated four times with
comparable results. (B) West-
ern blotting analysis of Tri-
ton X-100 extracts (E; 200 mg) or conditioned medium (M) from
BAE or BCE cells treated with 10 ng/ml of rFGF-2 (1) or with
control medium (2) for 17 h. The samples were electrophoresed
under nonreducing conditions. The protein blot was hybridized
with human VEGF IgG; antigen–antibody complexes were de-
tected as described in Materials and Methods. Recombinant
VEGF165 (10 ng) was run as a control in the leftmost lane. Molec-
ular masses are shown in kD on the left. This experiment was re-
peated three times with comparable results.
Figure 2. SK-Hep1–condi-
tioned medium induces FGF-2
and VEGF expression in en-
dothelial cells. (A) Right,
Western blotting analysis of
Triton X-100 extracts (200
mg) from BCE cells incu-
bated for 17 h with SK-Hep1
cell-conditioned medium
(SK-Hep1 c.m.) or with con-
trol medium (C). Recombi-
nant LMW FGF-2 (rFGF-2;
10 ng) was run as a control in
the leftmost lane. Left, 4 ml
of SK-Hep1 cell-conditioned
medium was concentrated
80-fold and analyzed by
Western blotting as described in Materials and Methods. 1 ng of
rFGF-2 was run in the same blot as a control. Antigen–antibody
complexes were detected as described in Materials and Methods.
Molecular masses are shown in kD between the two panels. The
positions of LMW and HMW FGF-2 bands are shown on the
right. This experiment was repeated three times with similar re-
sults. (B) Northern blotting analysis of total RNA (20 mg) from
BCE cells incubated for 2 h with either control medium (C) or
with SK-Hep1 cell-conditioned medium (SK-Hep1 c.m.) or 10 ng/
ml of rFGF-2 in the presence or absence of 10 mg/ml of neutraliz-
ing antibody to rFGF-2 (aFGF-2 IgG) or n.i. IgG (n.i. IgG). The
RNA blots were hybridized with a DIG-labeled cDNA probe to
human VEGF as described in Materials and Methods. GAPDH
mRNA is shown as a control. This experiment was repeated three
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absence or in the presence of doxycycline, a tetracycline an-
alogue (data not shown). However, HMW FGF-2 transfec-
tants had a higher growth rate than LMW FGF-2 transfec-
tants. Addition of doxycycline to the culture medium resulted
in a dramatic upregulation of both FGF-2 and VEGF165
expression by the LMW FGF-2 and the HMW FGF-2 trans-
fectants (Fig. 5) but did not affect FGF-2 or VEGF expres-
sion in control, vector-transfected cells (data not shown).
To confirm that VEGF expression in NIH 3T3 cells was
mediated by FGF-2, HMW FGF-2 and LMW FGF-2
transfectants were grown for 9 h in the presence of neu-
tralizing antibody to FGF-2. VEGF expression was char-
acterized by Northern blotting (data not shown) and by
Western blotting (Fig. 6). Addition of the antibody abol-
ished VEGF165 expression in a dose-dependent manner in
LMW FGF-2 transfectants but had no effect on HMW
FGF-2 transfectants. This result is consistent with previous
findings of different cell compartmentalization and mecha-
nisms of action of LMW FGF-2 and HMW FGF-2 (Quarto
et al., 1991b; Bikfalvi et al., 1995; Klein et al., 1996).
These data showed that VEGF expression is modulated
by endogenous FGF-2 as well as by exogenous FGF-2.
VEGF upregulation by endogenous LMW FGF-2 requires
release of FGF-2 from the cells and interaction with cell
membrane receptors. In contrast, endogenous HMW
FGF-2 acts through an intracellular mechanism.
FGF-2 Induces VEGF Expression in the Endothelial 
Cells of Growing Capillaries
To test the hypothesis that FGF-2 can upregulate endothe-
lial cell expression of VEGF in vivo, we used the angio-
Figure 4. FGF-2 and VEGF
expression in NIH 3T3 cells
transfected with FGF-2
cDNA. (A) FGF-2 expres-
sion. Triton X-100 extracts
(50  mg) of clones of NIH 3T3
cells transfected with the
cDNAs for HMW (clones 1
and 2), LMW (clones 3 and 4)
or WT FGF-2, or from con-
trol cells transfected with the vector alone (ZIPNEO) were ana-
lyzed by Western blotting with antibody to human FGF-2. Recombi-
nant LMW FGF-2 (rFGF-2; 10 ng) was run as a control in the
leftmost lane. (B) VEGF expression. Medium conditioned by the
clones of FGF-2 transfectants shown in A was analyzed by West-
ern blotting with antibody to VEGF. Recombinant VEGF165 (10 ng)
was run as a control in the leftmost lane. Western blotting was
carried out under reducing conditions as described in Materials
and Methods. Molecular masses are shown in kD on the left. This
experiment was repeated three times with similar results. (C)
Northern blotting analysis of total RNA (20 mg) from clones of
NIH 3T3 cells transfected with the cDNAs for HMW (clone 1),
LMW (clone 3) or WT FGF-2, or from control cells transfected
with the vector alone (ZIPNEO). The RNA blot was hybridized
with a DIG-labeled cDNA probe to human VEGF as described
in Materials and Methods. The position of 28 S and 18 S riboso-
mal RNA is shown on the left. 18S ribosomal RNA is shown as a
control. This experiment was repeated three times with compara-
ble results.
Figure 3. Antibody to VEGF inhibits FGF-2–induced endothe-
lial cell proliferation. Growth curves of HUVE (A and B) or
HAE (C and D) cells in the absence (h) or in the presence of 10
ng/ml of FGF-2 (e) (A and C) or 30 ng/ml of VEGF (m) (B and
D) without or with addition of either 10 mg/ml of anti-VEGF (m)
or anti–FGF-2 (s) or n.i. IgG (j). The cells were grown and
counted as described in Materials and Methods. Each point rep-
resents mean and standard deviation of triplicate samples from a
representative experiment.
genesis assay in the mouse cornea. Hydron pellets contain-
ing either 50 ng of rFGF-2 or no rFGF-2 were implanted in
corneal pockets of C57B mice 1 mm away from the limbic
vessels. 6 d after implantation, when maximum capillary
formation was observed in eyes with the rFGF-2 pellets,
30-mm sagittal sections of the entire eye were prepared
and analyzed both by in situ hybridization and by immu-
nohistochemistry.
In situ hybridization with a DIG-labeled antisense
VEGF riboprobe of sections of eyes that received sham
pellets showed that the endothelial cells of the limbic ves-
sels expressed no detectable VEGF mRNA (Fig. 7 A). In
sections of eyes that received rFGF-2 pellets, the VEGF
riboprobe hybridized to VEGF mRNA present in the en-
dothelial cells of the newly formed capillaries in the limbic
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series at high magnification (1,5003) showed that the
VEGF-expressing endothelial cells were predominantly
located in branching vessels (Fig. 8). The probe did not hy-
bridize significantly to occasional fibroblasts or other cell
types present in the corneal stroma (Figs. 7 and 8).
Immunostaining with antibody to VEGF showed that
the quiescent vessels of the limbic region of corneas that
received sham pellets had no VEGF (Fig 9). In sections of
eyes that received rFGF-2 pellets, the endothelium of
newly formed capillaries stained intensely with VEGF IgG
(Fig. 10). No other cell types present in the corneal stroma,
except occasional cells adjacent to the vessels’ lumina,
were stained. These cells may represent accessory vascular
cells (e.g., pericytes), acute inflammatory infiltrates or en-
dothelial cells of adjacent, collapsed capillaries. It is note-
worthy that significant hybridization of the VEGF ribo-
probe occurred only to cells surrounding the lumina (Figs.
7 and 8). All the periluminal cells stained with VEGF anti-
body also stained positively with antibody to vWF, an en-
dothelial cell marker, confirming that the VEGF mRNA-
producing cells were indeed endothelial cells (Figs. 9 and
10). Thus, although no VEGF is expressed by quiescent
vascular endothelium, induction of angiogenesis with
rFGF-2 results in VEGF expression by the endothelial
cells of forming capillaries.
Endothelial Cell VEGF Mediates
FGF-2–induced Angiogenesis
To investigate the functional significance of endothelial
cell expression of VEGF during FGF-2–induced angiogen-
esis, 18 mice that received corneal implants of pellets con-
taining rFGF-2 (50 ng) in both eyes were randomized into
three groups of six animals and given i.v. injections of ei-
ther PBS, PBS containing n.i. IgG (100 mg), or neutralizing
anti-human VEGF monoclonal antibody (100 mg). This
antibody neutralizes mouse VEGF in in vitro proliferation
assay almost as efficiently as human VEGF (Fig. 11; see
Fig. 3 for comparison). The mice were injected 1 d before
pellet implantation and on postoperative days 1 and 3. The
corneas were photographed on day 5.
The animals injected with anti-VEGF antibody consis-
tently showed markedly reduced angiogenesis relative to
control mice injected with PBS or n.i. IgG. As shown in
Fig. 12, the length of the vessels was the same in the three
groups. However, the capillaries of mice treated with anti-
VEGF antibody appeared to be consistently reduced in
number, and were thinner and less branched than in con-
trol animals. Similar results were obtained when the
VEGF antibody (1 mg) or n.i. IgG were added in the same
pellets containing rFGF-2 (Fig. 13).
To quantitate these effects, the number of vessels was
measured on enlarged photographs of all the eyes. Because
vessel branching also appeared to be reduced in antibody-
treated animals, the vessels were counted both proximally to
and distally from the limbus (i.e., close to the pellet). As
shown in Table I, in control mice the number of vessels distal
from the limbus was 2.0- to 2.5-fold higher than in the para-
limbic region. In mice receiving VEGF antibody either by
intravenous injection or by corneal implant the number of
vessels proximal to the limbic region showed only 12 and 26%
decrease, respectively. However, distally from the limbus, the
systemic and the topical antibody treatments resulted in
Figure 5. FGF-2 and VEGF expression in NIH 3T3 cells trans-
fected with FGF-2 cDNA under control by the tetracycline-
dependent transactivator. NIH 3T3 cells transfected with the
cDNAs for either LMW FGF-2 or HMW FGF-2 cDNA under
control by the tetracycline-dependent transactivator were grown
for 24 h in serum-free medium with (1) or without (2) addition
of 1 mg/ml of doxycycline. The conditioned medium was collected
and the cells were lysed with Triton X-100. Cell extracts and con-
centrated media were analyzed by Western blotting under nonre-
ducing conditions as described in Materials and Methods. (A)
Western blotting analysis of cell extracts (50 mg) with antibody to
FGF-2. Extract of NIH 3T3 cells transfected with wt FGF-2
cDNA (WT FGF-2) was run as a control in the rightmost lane.
(B) Western blotting analysis of conditioned media with antibody
to VEGF. The samples were electrophoresed under nonreducing
conditions. Recombinant VEGF165 (10 ng) was run as a control in
the rightmost lane. Molecular masses are shown in kD on the left
of each panel. This experiment was repeated twice with compara-
ble results.
Figure 6. Effect of anti–FGF-
2 antibody on VEGF expres-
sion by NIH 3T3 cells trans-
fected with LMW FGF-2 or
HMW FGF-2 cDNA. West-
ern blotting analysis of me-
dium conditioned by LMW
FGF-2 or HMW FGF-2
trans-fectants (clones 1 and 3
shown in Fig. 4) in the ab-
sence or in the presence of
the indicated concentrations
of anti-FGF-2 antibody
(aFGF-2) or n.i. (n.i.) IgG
(50  mg/ml). (A) LMW FGF-2 transfectants (clone 3). (B) HMW
FGF-2 transfectants (clone 1). FGF-2 expression by these clones is
shown in Fig. 4 A. The cells were preincubated for 3 h in serum-
free medium with or without the indicated concentrations of anti–
FGF-2 antibody or n.i. IgG; the medium was replaced with fresh,
serum-free medium with or without anti–FGF-2 antibody or n.i.
IgG and the incubation was continued for 9 h. The conditioned
medium was analyzed by Western blotting under reducing condi-
tions with anti-VEGF antibody as described in Materials and
Methods. Recombinant VEGF165 (10 ng) was run as a control in
the leftmost lane of the gels shown in A and B. This experiment
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Figure 7. Expression of VEGF mRNA by vascu-
lar endothelium in vivo. In situ hybridization
with DIG-labeled sense or antisense VEGF ribo-
probes of adjacent 30-mm sections of mouse cor-
neas that received either (A) sham pellets or
(B) pellets containing 50 ng of rFGF-2. Implan-
tation of pellets in the cornea, preparation of the
probes, and in situ hybridization were carried out
as described in Materials and Methods. Contrast
was enhanced by computer to increase the ap-
pearance of the reaction product. Arrowheads,
vessel’s wall. (A) Sections of limbic vessels show
no hybridization with the probes. (B) Sections of
newly forming capillaries in the stroma of the
cornea show hybridization of the endothelium
with the antisense but not with the sense probe.
Hybridization signals (brown-black staining) are
present only in the endothelium of newly formed
vessels in FGF-2–treated eyes.
40 and 50% decrease in vessel number, respectively, show-
ing that vessel branching was considerably reduced or abol-
ished by the VEGF antibody. Because only the endothelial
cells of forming capillaries in the cornea expressed VEGF
mRNA, the effect of the antibody must be mediated by the
neutralization of the endothelial cell-derived growth factor.
Therefore, endothelial cell VEGF represents a major auto-
crine effector of the angiogenic response induced by FGF-2.
Discussion
Experimental evidence has shown that angiogenesis is regu-
lated by a variety of growth factors and cytokines with a
paracrine mode of action. FGF-2 and VEGF are the most
potent angiogenesis inducers and have a synergistic effect
on angiogenesis (Pepper et al., 1992; Asahara et al., 1995).
In this work we provide evidence that vascular endothelial
cell-derived FGF-2 and VEGF are involved in a cascade of
growth factor activities that modulate angiogenesis with an
autocrine mechanism of action. In this cascade, endogenous
or exogenous FGF-2 regulates endothelial cell expression of
VEGF, which is a major autocrine mediator of FGF-
2-induced angiogenesis. These conclusions are based on the
following observations: (a) although quiescent endothelial
cells in vitro do not express VEGF, addition of exogenous
FGF-2 or upregulation of endogenous FGF-2 expression re-
sult in increased VEGF synthesis; (b) antibody to VEGF in-
hibits FGF-2-induced proliferation of endothelial cells; (c)
in cultured cells endogenous FGF-2 upregulates VEGF ex-
pression through both extracellular and intracellular mecha-
nisms: VEGF upregulation by LMW FGF-2 requires FGF-2
release from the cells and interaction with cell membrane
receptors; HMW FGF-2 acts through an intracellular mech-
anism; (d) although the quiescent endothelial cells of the
limbic vessels of mouse cornea express no VEGF, during
angiogenesis induced by implantation of FGF-2 pellets the
endothelial cells of newly formed capillaries express both
VEGF mRNA and protein; VEGF mRNA is located pri-
marily to the endothelium of branching vessels; and (e) sys-
temic administration of neutralizing VEGF antibody inhib-
its angiogenesis induced by FGF-2 in the mouse cornea.
Our cultured endothelial cells expressed significant
amounts of FGF-2 but no VEGF. Upregulation of VEGF
mRNA and protein required addition of exogenous FGF-2
or upregulation of endogenous FGF-2, indicating that the
endogenous levels of FGF-2 were not sufficient to induce
VEGF expression. This conclusion is also supported by our
experiments with NIH 3T3 fibroblasts transfected with FGF-2
cDNA and the tetracycline resistance transactivator. Be-
cause the tetracycline-controlled transactivator was leaky, in
the absence of doxycycline LMW FGF-2 and HMW FGF-2
transfectants expressed detectable amounts of FGF-2. How-
ever, the expression of VEGF was very low or below detec-
tion limit (refer to Fig. 5). Upregulation of FGF-2 synthesisSeghezzi et al. Autocrine Control of Angiogenesis by FGF-2 and VEGF 1667
by addition of doxycycline resulted in a dramatic increase in
VEGF expression. Therefore, the level of endogenous FGF-2
or the presence of exogenous FGF-2 are important factors in
the regulation of VEGF expression in endothelial cells.
Our characterization of NIH 3T3 cells transfected with
LMW FGF-2 or HMW FGF-2 cDNA showed that both
HMW FGF-2 and LMW FGF-2 upregulate VEGF expres-
sion. Transfectants that constitutively express high levels
of LMW FGF-2 or HMW FGF-2 also produce high levels
of VEGF, whereas control, vector-transfected cells ex-
press no VEGF. LMW FGF-2 and HMW FGF-2 transfec-
tants produce comparable levels of VEGF. However, the
high amounts of FGF-2 produced by these cells may mask
differences in the efficiency of VEGF regulation between
LMW FGF-2 and HMW FGF-2. Two observations suggest
that LMW FGF-2 may upregulate VEGF expression more
efficiently than HMW FGF-2. Treatment of endothelial
cells with SK-Hep1 cell-conditioned medium resulted in
five- and twofold increased synthesis of LMW FGF-2 and
HMW FGF-2, respectively. Concomitantly, VEGF mRNA
and VEGF165 levels were also upregulated. Addition of
neutralizing antibody to FGF-2 blocked the upregulation
of VEGF mRNA and protein. Because HMW FGF-2 is
primarily intracellular and acts through an intracrine
mechanism(s) (Bugler et al., 1991; Florkiewicz et al., 1991;
Quarto et al., 1991a,b; Renko et al., 1991; Bikfalvi et al.,
1995), the antibody did not neutralize HMW FGF-2 activ-
ity. However, the upregulation of HMW FGF-2 did not re-
sult in increased VEGF levels. This observation is consis-
tent with the results of our analysis of VEGF expression in
clones of NIH 3T3 cells transfected with FGF-2 cDNA
and the tetracycline resistance transactivator. In the ab-
sence of doxycycline, LMW FGF-2 transfectants expressed
low amounts of both LMW FGF-2 and VEGF. In contrast,
the HMW FGF-2 transfectants had higher levels of HMW
FGF-2 but expressed no VEGF (refer to Fig. 5).
Neutralizing antibody to FGF-2 abolished VEGF ex-
pression in NIH 3T3 cells that produce LMW FGF-2 but
had no effect on cells that express HMW FGF-2, showing
that LMW FGF-2 and HMW FGF-2 modulate VEGF ex-
Figure 8. Expression of
VEGF mRNA by the endo-
thelial cells of branching cap-
illaries.  Photomicrographs
taken in a through-focus se-
ries (1-mm steps) of a 30 mm-
thick section of mouse cor-
nea hybridized in situ with a
DIG-labeled antisense ribo-
probe to VEGF. A hydron
pellet containing 50 ng of
rFGF-2 was implanted in the
cornea 5 d before sectioning.
Implantation of the pellet in
the cornea, preparation of
the probes, and in situ hy-
bridization were carried out
as described in Materials and
Methods. Contrast was en-
hanced by computer to in-
crease the appearance of the
reaction product. Arrow-
heads,  the wall of a capillary
branching out of a larger ves-
sel (top left corner of each
panel). A homogenous hybridization signal is associated with the endothelium of the branching capillary (arrowheads, panels 2–5) but
not with the endothelium of the larger vessel. In panels 1 and 5 the capillary is below and above the focus plane, respectively.
Figure 9. Lack of VEGF expression in quiescent endothelium.
Adjacent 30-mm sections of mouse corneas that received pellets
with no FGF-2 were immunostained with antibody to mouse
VEGF (VEGF IgG) or to vWF (vWF IgG) or with n.i. IgG (n.i.
IgG) as described in Materials and Methods. The endothelium of
the limbic vessels (arrowheads) stains positively for vWF but not
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pression with different mechanisms of action. This finding
is consistent with previous observations that HMW FGF-2
is exclusively found intracellularly and accumulates in the
nucleus, whereas LMW FGF-2 is released by the cells and
binds to surface receptors (Bugler et al., 1991; Mignatti et
al., 1991; Florkiewicz et al., 1991; Quarto et al., 1991a,b;
Renko et al., 1991; Bikfalvi et al., 1995). LMW FGF-2 and
HMW FGF-2 modulate different cell functions, including
migration, proliferation and FGF receptor downregulation
(Bikfalvi et al., 1995). It has not been established whether
these cell functions are also mediated through VEGF ex-
pression.
Many tumor or transformed cells express high levels of
VEGF (Ferrara and Davis-Smyth, 1997). The upregula-
tion of VEGF expression in endothelial cells or in FGF-
2–transfected NIH 3T3 cells might result from the growth
stimulatory effect of FGF-2 or from nonspecific effects de-
rived from cell transformation. However, our analysis of
NIH 3T3 cells transfected with FGF-2 cDNA and the tet-
racycline resistance transactivator rules out this hypothe-
sis. Whereas expression of both FGF-2 and VEGF was
dramatically upregulated in the presence of doxycycline,
the cells had comparable growth rates in the presence or in
the absence of the antibiotic (data not shown). In the pres-
ence of doxycycline, LMW FGF-2 transfectants had lower
growth rates than HMW FGF-2 transfectants (data not
shown) but expressed comparable amounts of VEGF.
VEGF expression is regulated by a variety of factors, in-
cluding hypoxia, cytokines, and tumor promoters. FGF-2
upregulates VEGF levels in vascular smooth muscle cells
(Stavri et al., 1995). However, only hypoxia and advanced
glycation end products have been shown to regulate
VEGF expression in vascular endothelial cells (Liu et al.,
1995; Yamagishi et al., 1997). Our study is the first demon-
stration that VEGF expression in endothelial cells is mod-
ulated by FGF-2, a potent angiogenesis inducer. This find-
ing has several important implications. First, VEGF is an
important downstream mediator of the angiogenic activity
of FGF-2, as shown by the inhibitory effect of VEGF anti-
body in vitro and in vivo. Second, although other cell
types, including pericytes, smooth muscle cells, and in-
flammatory cells may participate in angiogenesis, capillary
formation can be mediated by endothelial cell-derived
growth factors through an autocrine mechanism indepen-
dent of accessory cells. Third, FGF-2 and VEGF have syn-
ergistic effects on angiogenesis (Pepper et al., 1992; Asa-
hara et al., 1995). Thus, a cascade of autocrine events in
which one angiogenic factor upregulates the other appears
to represent a very efficient mechanism for angiogenesis.
Recently, FGF-2 antibodies have been shown to block
VEGF-induced angiogenesis in vitro (Mandriota and Pep-
per, 1997). Although this effect is opposite to the one we
report here, it is consistent with our observation of an au-
tocrine mechanism of angiogenesis mediated by FGF-2
and points to complex interactions between FGF-2 and
VEGF. It is possible that endogenous endothelial cell
Figure 10. VEGF expression in the endothelium
of newly formed capillaries. Adjacent 30-mm sec-
tions of mouse corneas that received pellets con-
taining 50 ng of rFGF-2 were immunostained
with antibody to mouse VEGF (VEGF IgG) or
to vWF (vWF IgG) or with n.i. IgG (n.i. IgG) as
described in Materials and Methods. The endo-
thelium of newly formed capillaries (arrow-
heads) in the stroma of the cornea stains posi-
tively both for vWF and for VEGF. Some
paraluminal cells also stain positively with both
VEGF and vWF antibody.
Figure 11. Effect of mono-
clonal antibody to human
VEGF on endothelial cell
proliferation induced by
mouse VEGF. Growth curves
of HUVE cells in the ab-
sence (h) or in the presence
of 30 ng/ml of mouse VEGF
(r) and of either monoclonal
anti-human VEGF antibody
(m, 10 mg/ml; n, 30 mg/ml) or
n.i. IgG (h, 10 mg/ml; j, 30
mg/ml). The cells were grown and counted as described in Materi-
als and Methods. Each point represents mean and standard devi-
ation of triplicate samples from a representative experiment.Seghezzi et al. Autocrine Control of Angiogenesis by FGF-2 and VEGF 1669
FGF-2 is required for efficient angiogenesis and/or that
the simultaneous presence of both FGF-2 and VEGF in
vascular endothelial cells is required for angiogenesis in
the adult organism. Mice genetically deficient in FGF-2
(FGF-2 knockout) have a normal vasculature and no ap-
parent defects related to impaired angiogenesis (Ortega et
al., 1998; Zhou et al., 1998). However, whereas VEGF ex-
pression during development may be modulated by factors
other than FGF-2, the levels of VEGF in the endothelium
of forming capillaries in adult FGF-2 knockout mice have
not yet been characterized. More important, whether
FGF-2 knockout mice have normal VEGF levels and an-
giogenesis in pathological settings such as tumor growth
also remains to be investigated.
Our in vivo angiogenesis experiments with the mouse cor-
nea show that FGF-2 also modulates endothelial cell expres-
sion of VEGF in vivo, and that endothelial cell VEGF is an
important, autocrine effector of FGF-2–induced angiogenesis.
Consistent with previous findings, our in situ hybridiza-
tion and immunohistochemistry experiments showed that
the endothelium of the quiescent limbic vessels of the
mouse cornea does not express VEGF. However, after
stimulation with FGF-2, the endothelial cells of newly
formed capillaries produce both VEGF mRNA and pro-
tein. The analysis of VEGF mRNA in several tumors has
shown expression in the tumor cells but not in the endo-
thelium of the tumor vasculature (Ferrara and Davis-
Smyth, 1997). Conversely, immunohistochemical studies
have shown VEGF associated with the endothelium of tu-
mor capillaries, indicating that VEGF secreted by tumor
cells is bound by its receptors present exclusively on en-
dothelial cells (Plate et al., 1992, 1994; Brown et al., 1993;
Qu-Hong et al., 1995). In these studies the relative abun-
dance of VEGF transcript in the tumor cells might mask
the VEGF mRNA of the endothelial cells. Our experi-
mental model of angiogenesis in the mouse cornea obvi-
ates the problem of identifying the source of endothelium-
associated VEGF, since only occasional fibroblasts are
normally present in the stroma of the cornea. Inflamma-
tory cells may be present in the cornea during angiogene-
sis. However, in our in situ hybridization experiments, the
VEGF mRNA probe hybridized significantly only to
vWF–positive cells of newly formed capillaries, indicating
endothelial cells as the major source of VEGF.
Figure 12. Effect of anti-VEGF antibody on
FGF-2–induced angiogenesis. Hydron pellets
containing 50 ng of rFGF-2 were implanted in
the cornea of both eyes of 18 Swiss Webster mice
as described in Materials and Methods. The ani-
mals were randomized into three groups of six
mice and given i.v. injections of either PBS or
PBS containing n.i. IgG (100 mg) or neutralizing
anti-human VEGF monoclonal antibody (VEGF
IgG; 100 mg) 1 d before pellet implantation and
on postoperative days 1 and 3. The corneas were
photographed by slit-lamp biomicroscopy on day
5 after implantation of the pellet. The eyes of the
animals injected with VEGF antibody have
fewer and thinner corneal limbic capillaries than
those of animals injected with PBS or n.i IgG.
An enlargement of the limbic area containing
the newly formed vessels is shown below each
photograph of the corresponding eye. This ex-
periment was repeated twice with comparable
results. In control mice that received corneal im-
plants of pellets containing 200 ng of human re-
combinant VEGF, the same treatment with the
VEGF antibody abolished the angiogenic re-
sponse almost completely (data not shown).The Journal of Cell Biology, Volume 141, 1998 1670
On the basis of our data, we cannot exclude that in the cor-
nea assay VEGF from cell types other than endothelial cells,
including smooth muscle cells, macrophages, or T cells
(Freeman et al., 1995; Stavri et al., 1995; McLaren et al.,
1996), may contribute to early stages of angiogenesis, e.g.,
capillary sprouting from the limbic vessel. However, our
finding that VEGF antibody did not significantly reduce
the number of capillaries sprouting from the limbic vessel but
did considerably decrease subsequent branching indicates
that the contribution of cell types other than endothelial
cells may be independent of VEGF. In contrast, VEGF de-
rived from endothelial cells may play a role at later stages
of angiogenesis. Whatever the contribution of other cell types
to angiogenesis, our finding that in vitro FGF-2–stimulated
endothelial cells rapidly (2–4 h) upregulate VEGF mRNA
expression suggests that in vivo VEGF receptors can be
more promptly saturated by the endothelial cell–derived
ligand with an autocrine mechanism than with a paracrine
mechanism by VEGF derived from other sources.
VEGF mRNA was located predominantly to sites of
vessel branching. Interestingly, FGF-2 has also been found
associated with the basal lamina of branching capillaries
(Cordon et al., 1990), indicating that FGF-2 and VEGF
may be primarily expressed by the endothelium of grow-
ing capillaries and play a role in vessel formation. This hy-
pothesis is confirmed by our finding that neutralizing
VEGF antibody dramatically inhibits FGF-2 induced an-
giogenesis in the mouse cornea. It is noteworthy that the
antibody appears to predominantly reduce branching of
the newly formed vessels, an observation that correlates
with the location of FGF-2 and VEGF.
A number of experimental and clinical studies have im-
plicated VEGF as a paracrine angiogenesis factor in dif-
ferent physiological and pathological settings. The levels
of VEGF in several tumors have been shown to correlate
with tumor vascularity, a negative prognostic indicator for
a variety of malignancies (Toi et al., 1994; Maeda et al.,
1996). However, other studies have failed to demonstrate
such correlation (Dvorak et al., 1995). The autocrine or
paracrine regulation of endothelial cell VEGF by FGF-2
may represent an important mechanism of angiogenesis
under conditions in which insufficient or no VEGF is de-
rived from other cell types. This autocrine mechanism may
be triggered by normal or tumor cell-derived FGF-2 or by
upregulation of endothelial cell FGF-2. Factors that regu-
late endothelial cell expression of FGF-2 are essentially
unknown. Some tumor cell lines secrete a peptide(s) that
upregulates endothelial cell expression of FGF-2 and in-
duces in vitro angiogenesis (Peverali et al., 1994). FGF-2
upregulation results in increased expression of urokinase,
a proteinase implicated in angiogenesis. Urokinase upreg-
Table I. Number of Capillaries Proximal to and Distal from the Limbic Region of the Cornea of Mice Receiving mAb to VEGF by 
i.v. Injection or by Corneal Implant in the FGF-2–Containing Pellet
i.v. injection Pellet
Proximal Distal Proximal Distal
vessel vessel vessel vessel
(n)* (%)( n )* (%)( n )* (%)( n )* (%)
PBS 15.7 6 1.1 100.0 41 6 3.1 97.2 — — — —
n.i. IgG 15.7 6 1.1 100.0 42.3 6 1.5 100.0 15.3 6 1.0 100.0 30.0 6 1.3 100.0
VEGF Ab 13.8 6 1.5 87.9‡ 25.2 6 0.9 59.6§ 11.3 6 0.9 73.8‡ 15.2 6 0.9 50.7§
*Mean of 12 eyes per group 6 SEM.
‡P , 0.01.
§P , 0.01.
Statistical analysis performed by analysis of variance.
Figure 13. Effect of anti-VEGF antibody on FGF-2–induced an-
giogenesis. Hydron pellets containing 50 ng of rFGF-2 with or
without 1 mg of anti-VEGF monoclonal antibody were implanted
in the cornea of both eyes of Swiss Webster mice as described in
Materials and Methods. Each group consisted of six animals. The
corneas were photographed by slit-lamp biomicroscopy on day 5
after implantation of the pellet. FGF-2 pellet: eyes that received
corneal implantation of pellets containing FGF-2 alone. FGF-2/
VEGF IgG pellet: eyes that received corneal implantation of pel-
lets containing FGF-2 and antibody to VEGF. The eyes that re-
ceived corneal implants of pellets containing FGF-2 and VEGF
antibody have fewer and thinner corneal limbic capillaries than eyes
that received corneal implants of pellets containing FGF-2 alone.Seghezzi et al. Autocrine Control of Angiogenesis by FGF-2 and VEGF 1671
ulation and in vitro angiogenesis are mediated by endothe-
lial cell FGF-2 with an autocrine mechanism of action (Pe-
verali et al., 1994). The purification and characterization of
this and other potential factors that upregulate endothelial
cell FGF-2 will be important for our comprehension of the
paracrine and autocrine mechanisms of angiogenesis.
In all the experiments we performed, i.v. or local admin-
istration of VEGF antibody consistently inhibited angio-
genesis. However, our antibody did not totally abrogate
FGF-2–induced capillary formation. This result can be ex-
plained by two hypotheses: (a) the monoclonal antibody
we used was raised against human VEGF: although we found
that in vitro it can completely neutralize mouse VEGF al-
most as efficiently as human VEGF, it is possible that in
vivo this antibody does not completely neutralize or the
doses we administered did not afford complete neutralization
of mouse VEGF; and (b) FGF-2 may not only act by in-
ducing endothelial cell expression of VEGF but also induce
angiogenesis through VEGF-independent mechanisms.
Mouse embryos lacking a single VEGF allele have several
abnormalities in their vasculature and die in utero (Car-
meliet et al., 1996; Ferrara et al., 1996), showing that FGF-2
alone is not sufficient for normal vasculogenesis and angio-
genesis during development. However, in the adult organ-
ism FGF-2 might at least in part complement the lack of
VEGF. Although these hypotheses await confirmation, our
experiments clearly show endothelial cell VEGF as a major
downstream mediator of the angiogenic activity of FGF-2.
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